Alkermes announced that nemvaleukin alfa, the company’s investigational, novel engineered interleukin-2 variant immunotherapy, has been granted an Innovation Passport for the treatment of mucosal melanoma under the Innovative Licensing and Access Pathway by the Medicines and Healthcare products Regulatory Agency, the regulatory body of the United Kingdom. The Innovation Passport designation is the entry point to the ILAP, which aims to accelerate time to market and facilitate patient access to medicines in the UK for life-threatening or seriously debilitating conditions, or conditions for which there is a significant patient or public health need. Benefits of ILAP include access to a range of development tools, such as the potential for a 150-day accelerated Marketing Authorization Application assessment, rolling review and a continuous benefit-risk assessment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALKS:
- Alkermes price target raised to $28 from $27 at BofA
- Alkermes reports interim award in arbitration proceedings with Janssen
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Alkermes positioned for ‘considerable value creation,’ says Piper Sandler
- Alkermes management to meet with Piper Sandler